The FDA should conduct their own study of the bioequivalence of the other generic Wellbutrin XL it approved and not rely on the drug makers.

FORBES: A Drug Recall That Should Frighten Us All About The FDA

The FDA should tighten the regulations for bioequivalence for narrow therapeutic window drugs, especially those that pharmacists and patients have already complained about not working.

FORBES: A Drug Recall That Should Frighten Us All About The FDA